Evidence map›Paper›PMID 25537531›Full record

ArticleBioorganic & medicinal chemistry2015

IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells.

Chandrabose Karthikeyan, Crystal Lee, Joshua Moore, Roopali Mittal, Esther A Suswam, Kodye L Abbott, Satyanarayana R Pondugula, Upender Manne, Narayanan K Narayanan, Piyush Trivedi and 1 more

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. 1Molecules (Basel, Switzerland) · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Chandrabose KarthikeyanSchool of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal 462033, MP, India.
Crystal LeeDepartment of Biomedical Sciences, College of Veterinary Medicine, Nursing and Allied Health, CVMNAH, Tuskegee University, Tuskegee, AL 36088, USA.
Joshua MooreDepartment of Biomedical Sciences, College of Veterinary Medicine, Nursing and Allied Health, CVMNAH, Tuskegee University, Tuskegee, AL 36088, USA.
Roopali MittalPediatric Gastroenterology and Nutrition, Oklahoma State University, Oklahoma City, OK 73104, USA.
Esther A SuswamDepartment of Pathology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Kodye L AbbottDepartment of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Satyanarayana R PondugulaDepartment of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Upender ManneDepartment of Pathology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Narayanan K NarayananNew York University School of Medicine, New York, NY, USA.
Piyush TrivediSchool of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal 462033, MP, India. Electronic address: piyush.trivedi@rgtu.net.
Amit K TiwariDepartment of Biomedical Sciences, College of Veterinary Medicine, Nursing and Allied Health, CVMNAH, Tuskegee University, Tuskegee, AL 36088, USA. Electronic address: atiwari@mytu.tuskegee.edu.
Tuskegee University · USAuburn University · USRajiv Gandhi Technical University · INUniversity of Alabama at Birmingham · USNew York University · USOklahoma State University Oklahoma City · US

Funding

TRAINING AND CAREER DEVELOPMENTU54CA118948 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UPENDER MANNE · 2005 to 2026
$26.6M
Research Education CoreU54CA118623 · NCI · TUSKEGEE UNIVERSITY · PI Fan Wu · 2005 to 2026
$20.2M
INFRASTRUCTURE IIG12MD007585 · NIMHD · TUSKEGEE UNIVERSITY · PI YATES, CLAYTON · 2012 to 2016
$4.6M
NCI NIH HHS U54 CA118623NCI NIH HHS U54 CA118948NIMHD NIH HHS G12 MD007585NIMHD NIH HHS G12MD007585-23
6 · The paper itself

Abstract

Naturally occurring condensed quinolines have anticancer properties. In efforts to find active analogues, we designed and synthesized eight polycyclic heterocycles with a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline framework (IND series). The compounds were evaluated for activity against colon (HCT-116 and S1-MI-80), prostate (PC3 and DU-145), breast (MCF-7 and MDAMB-231), ovarian (ov2008 and A2780), and hepatocellular (HepG2) cancer cells and against non-cancerous Madin Darby canine kidney (MDCK), mouse embryonic fibroblast (NIH/3T3), and human embryonic kidney cells (HEK293). IND-2, a 4-chloro-2-methyl pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline, exhibited more than ten-fold selectivity and potent cytotoxic activity against colon cancer cells relative to the other cancer and non-cancer cells. With five additional colon cancer cell lines (HT-29, HCT-15, LS-180, LS-174, and LoVo), IND-2 had similar cytotoxicity and selectivity, and sub-micromolar concentrations caused changes in the morphology of HCT-116 and HCT-15 cells. IND-2 did not activate the transactivating function of the pregnane X receptor (PXR), indicating that it does not induce PXR-regulated ABCB1 or ABCG2 transporters. Indeed, IND-2 was not a substrate of ABCB1 or ABCG2, and it induced cytotoxicity in HEK293 cells overexpressing ABCB1 or ABCG2 to the same extent as in normal HEK293 cells. IND-2 was cytotoxic to resistant colon carcinoma S1-MI-80 cells, approximately three- and five-fold more than SN-38 and topotecan, respectively. In HCT-116 colon cancer cells, IND-2 produced concentration-dependent changes in mitochondrial membrane potential, leading to apoptosis, and sub-micromolar concentrations caused chromosomal DNA fragmentation. These findings suggest that, by increasing apoptosis, IND-2 has potential therapeutic efficacy for colorectal cancer.

Indexed as

AnimalsAntineoplastic AgentsApoptosisColonic NeoplasmsDogsDrug Resistance, MultipleDrug Resistance, NeoplasmDrug Screening Assays, AntitumorHCT116 CellsHEK293 CellsHep G2 CellsHumansMadin Darby Canine Kidney CellsMCF-7 CellsMicePyrimidinesAntineoplastic AgentsPyrimidinesQuinolinesAnticancer drugsDrug resistanceNew drug developmentPlant analogues

Identifiers

PMID25537531
PMCPMC4301998
OpenAlexW1974600878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.